Skip to main content
Top
Published in: Immunity & Ageing 1/2022

Open Access 01-12-2022 | Influenza Vaccination | Research

The impact of circadian rhythms on the immune response to influenza vaccination in middle-aged and older adults (IMPROVE): a randomised controlled trial

Authors: Yihao Liu, Hui Zhang, Gang Yuan, Mi Yao, Bin Li, Jianying Chen, Yuling Fan, Ruohui Mo, Fenghua Lai, Xinwen Chen, Mengyuan Li, Binfeng Chen, Janet M. Lord, Sui Peng, KarKeung Cheng, Haipeng Xiao

Published in: Immunity & Ageing | Issue 1/2022

Login to get access

Abstract

Background

Vaccination is important in influenza prevention but the immune response wanes with age. The circadian nature of the immune system suggests that adjusting the time of vaccination may provide an opportunity to improve immunogenicity. Our previous cluster trial in Birmingham suggested differences between morning and afternoon vaccination for some strains in the influenza vaccine in older adults. Whether this effect is also seen in a younger age group with less likelihood of compromised immunity is unknown. We therefore conducted an individual-based randomized controlled trial in Guangzhou to test the hypothesis that influenza vaccination in the morning induces a stronger immune response in older adults than afternoon vaccination. We included adults in middle age to determine if the effect was also seen in younger age groups.

Results

Of the 418 participants randomised, 389 (93.1%, 191 middle-aged adults aged 50–60 years and 198 older adults aged 65–75 years) were followed up. Overall, there was no significant difference between the antibody titers (geometric mean /95% CI) after morning vs afternoon vaccination (A/H1N1: 39.9 (32.4, 49.1) vs. 33.0 (26.7, 40.7), p = 0.178; A/H3N2: 92.2 (82.8, 102.7) vs. 82.0 (73.8, 91.2), p = 0.091; B: 15.8 (13.9, 17.9) vs. 14.4 (12.8, 16.3), p = 0.092), respectively. However, in pre-specified subgroup analyses, post-vaccination titers for morning versus afternoon vaccination in the 65–75 years subgroup were (A/H1N1): 49.5 (36.7, 66.6) vs. 32.9 (24.7, 43.9), p = 0.050; (A/H3N2): 93.5 (80.6, 108.5) vs. 73.1 (62.9, 84.9), p = 0.021; (B): 16.6 (13.8, 20.1) vs. 14.4 (12.3, 17.0), p = 0.095, respectively. Among females, antibody titers for morning versus afternoon vaccination were (A/H1N1): 46.9 (35.6, 61.8) vs. 31.1 (23.8, 40.7), p = 0.030; (A/H3N2): 96.0 (83.5, 110.3) vs. 84.7 (74.4, 96.5), p = 0.176; (B): 14.8 (12.7, 17.3) vs. 13.0 (11.3, 14.9), p = 0.061, respectively. In the 50–60 years old subgroup and males, there were no significant differences between morning and afternoon vaccination.

Conclusions

Morning vaccination may enhance the immunogenicity to influenza vaccine in adults aged over 65 and women. An intervention to modify vaccination programs to vaccinate older individuals in the morning is simple, cost free and feasible in most health systems.
Appendix
Available only for authorised users
Literature
2.
go back to reference Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32(14):1730–5.CrossRef Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32(14):1730–5.CrossRef
3.
go back to reference Thompson W, Shay D, Weintraub E, Brammer L, Bridges C, Cox N, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40.CrossRef Thompson W, Shay D, Weintraub E, Brammer L, Bridges C, Cox N, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40.CrossRef
4.
go back to reference Grohskopf L, Sokolow L, Broder K, Walter E, Fry A, Jernigan D. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018–19 Influenza Season. MMWR Recomm Rep. 2018;67(3):1–20.CrossRef Grohskopf L, Sokolow L, Broder K, Walter E, Fry A, Jernigan D. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018–19 Influenza Season. MMWR Recomm Rep. 2018;67(3):1–20.CrossRef
5.
go back to reference Gross P, Hermogenes A, Sacks H, Lau J, Levandowski R. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Annals Intern Med. 1995;123(7):518–27.CrossRef Gross P, Hermogenes A, Sacks H, Lau J, Levandowski R. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Annals Intern Med. 1995;123(7):518–27.CrossRef
6.
go back to reference Duthie M, Windish H, Fox C, Reed S. Use of defined TLR ligands as adjuvants within human vaccines. Immunological Rev. 2011;239(1):178–96.CrossRef Duthie M, Windish H, Fox C, Reed S. Use of defined TLR ligands as adjuvants within human vaccines. Immunological Rev. 2011;239(1):178–96.CrossRef
7.
go back to reference Gupta R, Siber G. Adjuvants for human vaccines–current status, problems and future prospects. Vaccine. 1995;13(14):1263–76.CrossRef Gupta R, Siber G. Adjuvants for human vaccines–current status, problems and future prospects. Vaccine. 1995;13(14):1263–76.CrossRef
8.
go back to reference DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Engl J Med. 2014;371(7):635–45.CrossRef DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Engl J Med. 2014;371(7):635–45.CrossRef
9.
go back to reference Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nature Rev Immunol. 2018;18(7):423–37.CrossRef Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nature Rev Immunol. 2018;18(7):423–37.CrossRef
10.
go back to reference Phillips A, Gallagher S, Carroll D, Drayson M. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology. 2008;45(4):663–6.CrossRef Phillips A, Gallagher S, Carroll D, Drayson M. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology. 2008;45(4):663–6.CrossRef
11.
go back to reference Long J, Drayson M, Taylor A, Toellner K, Lord J, Phillips A. Morning vaccination enhances antibody response over afternoon vaccination: a cluster-randomised trial. Vaccine. 2016;34(24):2679–85.CrossRef Long J, Drayson M, Taylor A, Toellner K, Lord J, Phillips A. Morning vaccination enhances antibody response over afternoon vaccination: a cluster-randomised trial. Vaccine. 2016;34(24):2679–85.CrossRef
12.
go back to reference de Bree L, Mourits V, Koeken V, Moorlag S, Janssen R, Folkman L, et al. Circadian rhythm influences induction of trained immunity by BCG vaccination. J Clin Invest. 2020;130(10):5603–17.CrossRef de Bree L, Mourits V, Koeken V, Moorlag S, Janssen R, Folkman L, et al. Circadian rhythm influences induction of trained immunity by BCG vaccination. J Clin Invest. 2020;130(10):5603–17.CrossRef
13.
go back to reference Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021;11;31(11). Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021;11;31(11).
14.
go back to reference Govaert T, Thijs C, Masurel N, Sprenger M, Dinant G, Knottnerus J. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–5.CrossRef Govaert T, Thijs C, Masurel N, Sprenger M, Dinant G, Knottnerus J. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–5.CrossRef
15.
go back to reference Aspinall R, Andrew D. Thymic involution in aging. J Clin Immunol. 2000;20(4):250–6.CrossRef Aspinall R, Andrew D. Thymic involution in aging. J Clin Immunol. 2000;20(4):250–6.CrossRef
16.
go back to reference Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, et al. Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses. Immunity. 2017;46(1):120–32.CrossRef Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, et al. Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses. Immunity. 2017;46(1):120–32.CrossRef
17.
go back to reference Heaney JL, Phillips AC, Carroll D. Ageing, depression, anxiety, social support and the diurnal rhythm and awakening response of salivary cortisol. Int J Psychophysiol. 2010;78(3):201–8.CrossRef Heaney JL, Phillips AC, Carroll D. Ageing, depression, anxiety, social support and the diurnal rhythm and awakening response of salivary cortisol. Int J Psychophysiol. 2010;78(3):201–8.CrossRef
18.
go back to reference van Kerkhof LW, Van Dycke KC, Jansen EH, Beekhof PK, van Oostrom CT, Ruskovska T, et al. Diurnal Variation of Hormonal and Lipid Biomarkers in a Molecular Epidemiology-Like Setting. PLoS One. 2015;10(8):e0135652.CrossRef van Kerkhof LW, Van Dycke KC, Jansen EH, Beekhof PK, van Oostrom CT, Ruskovska T, et al. Diurnal Variation of Hormonal and Lipid Biomarkers in a Molecular Epidemiology-Like Setting. PLoS One. 2015;10(8):e0135652.CrossRef
19.
go back to reference Waggoner SN. Circadian Rhythms in Immunity. Curr Allergy Asthma Rep. 2020;20(1):2.CrossRef Waggoner SN. Circadian Rhythms in Immunity. Curr Allergy Asthma Rep. 2020;20(1):2.CrossRef
20.
go back to reference Early JO, Menon D, Wyse CA, Cervantes-Silva MP, Zaslona Z, Carroll RG, et al. Circadian clock protein BMAL1 regulates IL-1β in macrophages via NRF2. Proc Natl Acad Sci U S A. 2018;115(36):E8460–8.CrossRef Early JO, Menon D, Wyse CA, Cervantes-Silva MP, Zaslona Z, Carroll RG, et al. Circadian clock protein BMAL1 regulates IL-1β in macrophages via NRF2. Proc Natl Acad Sci U S A. 2018;115(36):E8460–8.CrossRef
21.
go back to reference Fortier E, Rooney J, Dardente H, Hardy M, Labrecque N, Cermakian N. Circadian variation of the response of T cells to antigen. J Immunol (Baltimore, Md: 1950). 2011;187(12):6291–300.CrossRef Fortier E, Rooney J, Dardente H, Hardy M, Labrecque N, Cermakian N. Circadian variation of the response of T cells to antigen. J Immunol (Baltimore, Md: 1950). 2011;187(12):6291–300.CrossRef
22.
go back to reference Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Aquir Immune Defic Syndr. 1990;3(2):144–51. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Aquir Immune Defic Syndr. 1990;3(2):144–51.
23.
go back to reference Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science (New York, NY). 2013;341(6153):1483–8.CrossRef Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science (New York, NY). 2013;341(6153):1483–8.CrossRef
24.
go back to reference Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annual Rev Cell Dev Biol. 2017;33:577–99.CrossRef Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annual Rev Cell Dev Biol. 2017;33:577–99.CrossRef
25.
go back to reference Sánchez-de Prada L, Ortiz de Lejarazu-Leonardo R, Castrodeza-Sanz J, Tamayo-Gómez E, Eiros-Bouza J, Sanz-Muñoz I. Do Vaccines Need a Gender Perspective? Influenza Says Yes! Frontiers Immunol. 2021;12:715688.CrossRef Sánchez-de Prada L, Ortiz de Lejarazu-Leonardo R, Castrodeza-Sanz J, Tamayo-Gómez E, Eiros-Bouza J, Sanz-Muñoz I. Do Vaccines Need a Gender Perspective? Influenza Says Yes! Frontiers Immunol. 2021;12:715688.CrossRef
26.
go back to reference Abdullah M, Chai PS, Chong MY, Tohit ER, Ramasamy R, Pei CP, et al. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cellular Immunol. 2012;272(2):214–9.CrossRef Abdullah M, Chai PS, Chong MY, Tohit ER, Ramasamy R, Pei CP, et al. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cellular Immunol. 2012;272(2):214–9.CrossRef
27.
go back to reference Denly L. The effect of sex on responses to influenza vaccines. Human Vaccines Immunotherapeutics. 2021;17(5):1396–402.CrossRef Denly L. The effect of sex on responses to influenza vaccines. Human Vaccines Immunotherapeutics. 2021;17(5):1396–402.CrossRef
28.
go back to reference Potluri T, Fink A, Sylvia K, Dhakal S, Vermillion M, Vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ vaccines. 2019;4:29.CrossRef Potluri T, Fink A, Sylvia K, Dhakal S, Vermillion M, Vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ vaccines. 2019;4:29.CrossRef
29.
go back to reference Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nature Rev Immunol. 2010;10(8):594–604.CrossRef Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nature Rev Immunol. 2010;10(8):594–604.CrossRef
30.
go back to reference Pedersen J. Hemagglutination-inhibition assay for influenza virus subtype identification and the detection and quantitation of serum antibodies to influenza virus. Methods Mol Biol (Clifton, NJ). 2014;1161:11–25.CrossRef Pedersen J. Hemagglutination-inhibition assay for influenza virus subtype identification and the detection and quantitation of serum antibodies to influenza virus. Methods Mol Biol (Clifton, NJ). 2014;1161:11–25.CrossRef
31.
go back to reference Jackson L, Campbell J, Frey S, Edwards K, Keitel W, Kotloff K, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015;314(3):237–46.CrossRef Jackson L, Campbell J, Frey S, Edwards K, Keitel W, Kotloff K, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015;314(3):237–46.CrossRef
32.
go back to reference Liebowitz D, Lindbloom J, Brandl J, Garg S, Tucker S. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infectious Diseases. 2015;15(9):1041–8.CrossRef Liebowitz D, Lindbloom J, Brandl J, Garg S, Tucker S. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infectious Diseases. 2015;15(9):1041–8.CrossRef
33.
go back to reference WHO. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization ; 2002. (document WHO/CDS/CSR/NCS/2002.5) WHO. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization ; 2002. (document WHO/CDS/CSR/NCS/2002.5)
34.
go back to reference Fitzner J, Qasmieh S, Mounts A, Alexander B, Besselaar T, Briand S, et al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018;96(2):122–8.CrossRef Fitzner J, Qasmieh S, Mounts A, Alexander B, Besselaar T, Briand S, et al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018;96(2):122–8.CrossRef
35.
go back to reference Zhuo L, Xu L, Ye J, Sun S, Zhang Y, Burstrom K, et al. Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey. Value Health. 2018;21(11):1330–7.CrossRef Zhuo L, Xu L, Ye J, Sun S, Zhang Y, Burstrom K, et al. Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey. Value Health. 2018;21(11):1330–7.CrossRef
Metadata
Title
The impact of circadian rhythms on the immune response to influenza vaccination in middle-aged and older adults (IMPROVE): a randomised controlled trial
Authors
Yihao Liu
Hui Zhang
Gang Yuan
Mi Yao
Bin Li
Jianying Chen
Yuling Fan
Ruohui Mo
Fenghua Lai
Xinwen Chen
Mengyuan Li
Binfeng Chen
Janet M. Lord
Sui Peng
KarKeung Cheng
Haipeng Xiao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2022
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-022-00304-w

Other articles of this Issue 1/2022

Immunity & Ageing 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.